Grant, phase 2 trial of patient-derived multitumor-associated antigen-specific t cells (MT-601) to treat relapsed/refractory diffuse large b-cell lymphoma (dlbcl)
Active Project Grant Awarded Last action
- Award ID
- HT9425261E440
- Recipient
-
Marker Therapeutics Inc. UEI CK3KR85CSP23
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $4,170,167
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 10% complete
- Place of performance
- Houston, TX 77021, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded Marker Therapeutics Inc. $4.17 million on August 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct a Phase 2 clinical trial of MT-601, a patient-derived multitumor-associated antigen-specific T-cell therapy, in patients with relapsed or refractory diffuse large B-cell lymphoma. The award funds research and development of this cellular immunotherapy designed to target multiple cancer-associated antigens simultaneously. Work is performed in Houston, Texas, with a period of performance through August 14, 2028. Marker Therapeutics is a small disadvantaged business specializing in T-cell immunotherapies for cancer treatment, with prior grant-funded development of MT-601 for pancreatic cancer and non-Hodgkin lymphoma and MT-401 for acute myeloid leukemia.
Quick answers
Who received award HT9425261E440?
HT9425261E440 was awarded to Marker Therapeutics Inc. by Defense Health Agency (Department of Defense) on August 15, 2026.
How much is award HT9425261E440 worth?
$4,170,167 has been obligated on HT9425261E440.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award